Suscribirse

High Rates of Prostate-specific Antigen Testing in Men with Evidence of Benign Prostatic Hyperplasia - 09/09/11

Doi : 10.1016/S0002-9343(98)00113-2 
JamesB Meigs, MD, MPH a, , MichaelJ Barry, MD a, Edward Giovannucci, MD b, c, EricB Rimm b, c : ScD, MeirJ Stampfer, MD b, c, Ichiro Kawachi, MD, PhD b, d
a General Medicine Division of the Medical Services (JBM, MJB), Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston, Massachusetts USA 
b Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital (EG, EBR, MJS, IK), Boston, Massachusetts USA 
c Departments of Epidemiology and Nutrition, Harvard School of Public Health (EG, EBR, MJS), Boston, Massachusetts USA 
d Departments of Health and Social Behavior (IK), Boston, Massachusetts USA 

*Requests for reprints should be addressed to James B. Meigs, MD, MPH, General Internal Medicine Unit S50-9, Massachusetts General Hospital, Boston, Massachusetts 02114

Abstract

Purpose: Benign prostatic hyperplasia is common among men who may be candidates for prostate cancer screening using prostate-specific antigen (PSA) testing. Patterns of PSA testing among men with evidence of benign prostatic hyperplasia have not been studied.

Methods: We examined the prevalence and correlates of a self-reported history of PSA testing. In 1994, 33,028 US health professionals without prostate cancer aged 47 to 85 years provided information on prior PSA testing, lower urinary tract symptoms characteristic of benign prostatic hyperplasia, history of prostatectomy, and prostate cancer risk factors. In 1995, a subset of 7,070 men provided additional information on diagnosis and treatment of benign prostatic hyperplasia.

Results: From 39% of men in their 50s to 53% of men in their 80s reported PSA testing in the prior year (P <0.0001 for trend with age). Men were more likely to report PSA testing if they had lower urinary tract symptoms characteristic of benign prostatic hyperplasia (age-adjusted odds ratio for severe symptoms 2.2, 95% confidence interval 1.8 to 2.6), a prior history of prostatectomy (age-adjusted odds ratio 1.1, 95% confidence interval 1.02 to 1.2), or a physician diagnosis of benign prostatic hyperplasia (odds ratio 1.9, 95% confidence interval 1.7 to 2.2; adjusted for age, signs or symptoms of benign prostatic hyperplasia, and prostate cancer risk factors).

Conclusions: These US health professionals reported preferential use of PSA testing among men least likely to benefit from early cancer detection (older men) and among men most likely to have a false-positive PSA result (men with benign prostatic hyperplasia). Physician and patient education are needed to promote more rational and selective use of this screening test.

El texto completo de este artículo está disponible en PDF.

Esquema


 Supported by Research Grants DK45779, CA55075, and HL35464 from The National Institutes of Health and by PORT II Grant No. HS 08397 from the Agency for Health Care Policy and Research.


© 1998  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 104 - N° 6

P. 517-525 - juin 1998 Regresar al número
Artículo precedente Artículo precedente
  • Discussion
| Artículo siguiente Artículo siguiente
  • Prostate Cancer Screening and Beliefs about Treatment Efficacy: A National Survey of Primary Care Physicians and Urologists
  • Floyd J Fowler, Lin Bin, Mary McNaughton Collins, Richard G Roberts, Joseph E Oesterling, John H Wasson, Michael J Barry

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.